INTRODUCING

NIOX VERO®

The technology of choice for FeNO testing.1

Designed for you

Unique FeNO algorithm

Our next-level analysis provides accurate results.

FeNODry™ Technology

FeNODry™ removes humidity from test samples.

Flow Rate Control™

Flow Rate Control prevents patients from failing a test.

Portable design

NIOX® is easy to move between multiple clinics.

Colour touchscreen

With NIOX®, FeNO testing is easy to navigate.

Designed for real life

NIOX® is designed for healthcare professionals. Whether you practise in primary or secondary care, the benefits of testing FeNO with NIOX® are clear: accurate, reliable, straightforward technology for the right result every time.

Paitient using the FeNO NIOX

The device of choice

Clinical researchers put their faith in FeNO too, with NIOX® the device of choice in thousands of trials across the globe.

Trusted around the world

NIOX® is designed for healthcare professionals. Whether you practise in primary or secondary care, the benefits of testing FeNO with NIOX® are clear: accurate, reliable, straightforward technology for the right result every time.

FAQ

FeNO (Fractional exhaled Nitric Oxide) is a biomarker for airway inflammation. Elevated FeNO levels can indicate eosinophilic inflammation, commonly found in asthma. Measuring FeNO helps confirm diagnosis and guide appropriate treatment.

NIOX VERO is a portable, non-invasive device that measures FeNO levels in a patient’s breath in just one minute. It provides immediate, quantitative results to support clinical decisions in asthma management.

Yes. The test is completely safe, non-invasive, and requires only a slow, steady exhalation through the mouthpiece. It’s suitable for both adults and children aged 4 and up.

NIOX VERO is designed for use in both primary care and specialist clinics. Its ease of use and portability make it ideal for GPs, paediatricians, allergists, pulmonologists, and asthma educators.

FeNO levels can be measured during initial diagnosis, at follow-up appointments, when considering changes in corticosteroid therapy, or when asthma control deteriorates.

  • Low FeNO (<25 ppb adults / <20 ppb children): Low likelihood of eosinophilic inflammation

  • Intermediate FeNO (25–50 ppb / 20–35 ppb): Possible inflammation

  • High FeNO (>50 ppb / >35 ppb): Strong indicator of eosinophilic inflammation, likely to respond to corticosteroids
    Always interpret in context with clinical findings.

No. FeNO is complementary to spirometry. While spirometry measures lung function, FeNO provides insight into airway inflammation, helping to identify steroid-responsive asthma.

Ready to elevate your asthma care?

Healthcare professionals – Request a quote today and discover how NIOX VERO can transform your respiratory diagnostics with precision, speed, and confidence.

Take the next step